Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer. - Sabbioni S; Guerriero P; Shankaraiah RC; Masatti L; Michilli A; Bassi C; D'Abundo L; Moshiri F; De Siena B; Simoni E; Astolfi L; Gramantieri L; et al. (Cell death discovery, 2026)